Drug Discovery · Eindhoven, Netherlands · Founded 2019 · Privately Held (backing)
Developer of small-molecule cancer drugs designed to stabilize the direct interaction of oncogenic proteins. Ambagon Therapeutics is based in Eindhoven, Netherlands and was founded in 2019. It has raised $108 million across 3 recorded rounds; the latest was a $5 million early-stage round in Jan 2025.
Last price · $/share
—
Implied valuation
—
Total raised
$108.0M
Last round
Early Stage VC
Jan 2025
Team — not yet on record
No current team members for Ambagon Therapeutics are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ambagon Therapeutics with a free account
·The complete investor list: 13 names
·Watch Ambagon Therapeutics: the Monday email on marks, rounds and moves
